Subsequently, studies in HBE cultures from patients with CF were critical for the successful development of small‐molecule CFTR modulator drugs that restore the chloride channel function of the mutated CFTR protein and provide unprecedented benefits for currently up to 90% of CF patients who are eligible for these therapies (Graeber & Mall, 2023). Here, CFTR is linked to cystic fibrosis.